Efficacy of 5% imiquimod cream in a patient with classic kaposi sarcoma
| dc.contributor.author | Gündüz K. | |
| dc.contributor.author | Günay Ü. | |
| dc.contributor.author | Inanir I. | |
| dc.contributor.author | Gençoǧlan G. | |
| dc.contributor.author | Temiz P. | |
| dc.date.accessioned | 2025-04-10T11:14:34Z | |
| dc.date.available | 2025-04-10T11:14:34Z | |
| dc.date.issued | 2012 | |
| dc.description.abstract | Background: The classic Kaposi sarcoma is most common in the Mediterranean po-pulation over 50 years of age and presents with reddish-brown papules and nodules particularly on the lower limbs. Treatment depends on the clinical presentation and extension of lesions. Imiquimod is as an immune response modifier with antiangio-genic activity. Main observations: We present a 74-year-old man with classic Kaposi sarcoma who had multiple, small, violaceous papules and nodules on the trunk and extremities with a history of 14 years. He complained particularly from plantar hyperkeratotic painful nodules. Treatment with imiquimod 5% cream under occlusion resulted with almost complete regression within 12 weeks. No local or systemic side effects were observed. Conclusions: Topical imiquimod was a safe and effective therapy in our patient with classic Kaposi sarcoma. | |
| dc.identifier.DOI-ID | 10.3315/jdcr.2012.1099 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/50308 | |
| dc.title | Efficacy of 5% imiquimod cream in a patient with classic kaposi sarcoma | |
| dc.type | Article |